Endovascular Aneurysm Sealing and Chimney Endovascular Aneurysm Sealing in the Treatment of Type Ia and Type III Endoleaks After Endovascular Aneurysm Repair.


Journal

Annals of vascular surgery
ISSN: 1615-5947
Titre abrégé: Ann Vasc Surg
Pays: Netherlands
ID NLM: 8703941

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 25 03 2019
revised: 07 05 2019
accepted: 07 05 2019
pubmed: 9 8 2019
medline: 10 3 2020
entrez: 9 8 2019
Statut: ppublish

Résumé

The aim of this study was to report the treatment of type Ia and type III endoleaks after endovascular aneurysm repair (EVAR) or chimney EVAR using endovascular aneurysm sealing (EVAS) and chimney EVAS. Ten consecutive patients who underwent the EVAS procedure to treat endoleaks after EVAR were retrospectively included between July 2015 and July 2017. Technical success of EVAS was defined as a successful sealing of the Nellix endograft with visceral vessel patency on intraoperative completion angiography. The median time between EVAR and EVAS procedure was 41.5 months (29-81.8). Eight patients had an elective procedure, whereas 2 were treated in emergency. Chimney endografts were placed during the EVAS procedure in 4 patients, whereas classic EVAS was performed for the other 6 patients. The median procedural time was 222.5 min (138.8-418.8). The technical success was achieved for all patients. The median length of stay after EVAS was 7 days (6.8-14). No death related to abdominal aortic aneurysms or vascular complications were reported for a median follow-up duration of 13.5 months (6.3-25.5). A reintervention was required for 2 patients who developed persistent type II and type Ia endoleaks, which were successfully treated using an embolization procedure. EVAS and chimney EVAS in the treatment of type Ia and type III endoleaks after EVAR and chimney EVAR are technically feasible. Short-term follow-up suggests that the procedure is a safe and efficient therapeutic alternative to manage disabled EVAR.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study was to report the treatment of type Ia and type III endoleaks after endovascular aneurysm repair (EVAR) or chimney EVAR using endovascular aneurysm sealing (EVAS) and chimney EVAS.
METHODS METHODS
Ten consecutive patients who underwent the EVAS procedure to treat endoleaks after EVAR were retrospectively included between July 2015 and July 2017. Technical success of EVAS was defined as a successful sealing of the Nellix endograft with visceral vessel patency on intraoperative completion angiography.
RESULTS RESULTS
The median time between EVAR and EVAS procedure was 41.5 months (29-81.8). Eight patients had an elective procedure, whereas 2 were treated in emergency. Chimney endografts were placed during the EVAS procedure in 4 patients, whereas classic EVAS was performed for the other 6 patients. The median procedural time was 222.5 min (138.8-418.8). The technical success was achieved for all patients. The median length of stay after EVAS was 7 days (6.8-14). No death related to abdominal aortic aneurysms or vascular complications were reported for a median follow-up duration of 13.5 months (6.3-25.5). A reintervention was required for 2 patients who developed persistent type II and type Ia endoleaks, which were successfully treated using an embolization procedure.
CONCLUSIONS CONCLUSIONS
EVAS and chimney EVAS in the treatment of type Ia and type III endoleaks after EVAR and chimney EVAR are technically feasible. Short-term follow-up suggests that the procedure is a safe and efficient therapeutic alternative to manage disabled EVAR.

Identifiants

pubmed: 31394252
pii: S0890-5096(19)30524-2
doi: 10.1016/j.avsg.2019.05.029
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

317-325

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Fabien Lareyre (F)

Cardiovascular Surgery Unit, Cardio Thoracic Centre of Monaco, Monaco; Université Côte d'Azur, CHU, Inserm, C3M, Nice, France. Electronic address: fabien.lareyre@gmail.com.

Claude Mialhe (C)

Cardiovascular Surgery Unit, Cardio Thoracic Centre of Monaco, Monaco.

Carine Dommerc (C)

Cardiovascular Surgery Unit, Cardio Thoracic Centre of Monaco, Monaco.

Juliette Raffort (J)

Université Côte d'Azur, CHU, Inserm, C3M, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH